October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 9, 2014

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

October 7, 2014

Actavis and Durata Therapeutics on Monday announced that they have entered into a definitive merger agreement.

October 2, 2014

Seroyal on Wednesday announced the Canadian release of Genestra Brands Statin Care, a balanced nutritional supplement formulated to provide nutritional support for patients taking statin medications.

September 30, 2014

Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths.

September 30, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

September 26, 2014

Camber Pharmaceuticals announced the launch of raloxifene hydrochloride, USP tablets in 60-mg dosage strengths.

September 16, 2014

The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.

September 15, 2014

Bayer HealthCare on Monday launched Aleve PM, the first over-the-counter nighttime product with a safe sleep aid plus the 12-hour pain-relieving strength of Aleve.

September 15, 2014

Hyland’s launched Hyland’s Baby Nighttime teething tablets, a nighttime version to join its best-selling infant oral pain reliever Hyland’s Baby teething tablets in the $40 million infant oral pain segment. 

September 12, 2014

Lupin Limited and Salix Pharmaceuticals on Friday announced that they have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada. 

September 5, 2014

Purdue Pharma on Thursday shared results from several studies evaluating its investigational pain medication Hysingla ER.

September 5, 2014

Purdue Pharma on Thursday presented results from two epidemiological studies evaluating the reformulation of OxyContin. 

September 4, 2014

Teva Pharmaceutical on Thursday announced the launch of generic Baraclude (entecavir) tablets in 0.5-mg and 1-mg dosage strengths. The company was the first to file, giving it 180 days of marketing exclusivity for the drug. 

September 2, 2014

Acura Pharmaceuticals last week announced that it has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology.

September 2, 2014

The asthma treatment market value will grow from approximately $15.9 billion in 2013 across eight major countries — the United States, United Kingdom, France, Germany, Spain, Italy, Japan and Australia — to $23.1 billion by 2023, according to research and consulting firm GlobalData.

August 25, 2014

ViiV Healthcare announced that the Food and Drug Administration has approved Triumeq (abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg) tablets for the treatment of HIV-1 infection.

August 22, 2014

The Drug Enforcement Administration issued a final rule rescheduling hydrocodone combination products from schedule III to schedule II of the Controlled Substances Act.

August 20, 2014

Kiss My Face introduced a new range of sun care options, which includes an expansion of its specialty sun offerings.

August 20, 2014

Pfizer successfully switched Nexium to over-the-counter in late May, and with that brought a $6 billion book of prescription business to antacid aisles, according to IMS Health data compiled over 2012.

August 14, 2014

Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.